Overview

Gender

male

Andrew J. Oakley joined Novimmune as Chief Financial Officer in March 2014, bringing with him over 30 years of professional experience in pharmaceutical, financial, and industrial organizations.
Previously, Andrew served for ten years as Executive Vice President and Chief Financial Officer at Actelion Ltd., a global biopharmaceutical leader headquartered in Switzerland.
During his tenure there, Andrew led the financial functions of the company as it grew from 200 employees with sales of CHF 100 million into a global enterprise with 2,500 employees and sales of CHF 1.7 billion. The company's market capitalization also multiplied from CHF 1.5 billion to CHF 7.5 billion during that time.

Prior to Actelion, Andrew was a senior finance executive with Accenture, the global business consultancy, and held a number of additional senior management and finance roles at financial and industrial organisations in Australia, the UK and the US.
An Australian citizen, Andrew Oakley holds a Bachelor of Economics from Macquarie University in Sydney and an MBA from the London Business School. He also holds an ACA qualification from the Australian Institute of Chartered Accounting.